| Technologies for enhanced efficacy of DNA vaccines. | |
| | |
MedLine Citation:
|
PMID: 22309668 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Despite many years of research, human DNA vaccines have yet to fulfill their early promise. Over the past 15 years, multiple generations of DNA vaccines have been developed and tested in preclinical models for prophylactic and therapeutic applications in the areas of infectious disease and cancer, but have failed in the clinic. Thus, while DNA vaccines have achieved successful licensure for veterinary applications, their poor immunogenicity in humans when compared with traditional protein-based vaccines has hindered their progress. Many strategies have been attempted to improve DNA vaccine potency including use of more efficient promoters and codon optimization, addition of traditional or genetic adjuvants, electroporation, intradermal delivery and various prime-boost strategies. This review summarizes these advances in DNA vaccine technologies and attempts to answer the question of when DNA vaccines might eventually be licensed for human use. |
| | |
Authors:
|
Fadi Saade; Nikolai Petrovsky |
Related Documents
:
|
22326778 - The extradomain a of fibronectin (eda) combined with poly(i:c) enhances the immune resp... 22686468 - Saccharomyces as a vaccine against systemic candidiasis. 22848478 - Protection against enterovirus 71 with neutralizing epitope incorporation within adenov... 22795098 - Factors associated with the intention to recommend pertussis vaccination for postpartum... 18352468 - Out-of-plane (e, 2e) experiments on helium l=0, 1, 2 autoionizing levels. 16988458 - Immunological responses of neonates and infants to dna vaccines. |
Publication Detail:
|
Type: Journal Article; Research Support, N.I.H., Extramural; Review |
Journal Detail:
|
Title: Expert review of vaccines Volume: 11 ISSN: 1744-8395 ISO Abbreviation: Expert Rev Vaccines Publication Date: 2012 Feb |
Date Detail:
|
Created Date: 2012-02-07 Completed Date: 2012-06-05 Revised Date: 2013-05-20 |
Medline Journal Info:
|
Nlm Unique ID: 101155475 Medline TA: Expert Rev Vaccines Country: England |
Other Details:
|
Languages: eng Pagination: 189-209 Citation Subset: IM |
Affiliation:
|
Vaxine Pty Ltd, Bedford Park, Adelaide 5042, Australia. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adjuvants, Immunologic
/
administration & dosage,
adverse effects Animals Cancer Vaccines* / administration & dosage, adverse effects, genetics, immunology Clinical Trials as Topic Communicable Diseases / immunology* Cytokines / genetics, immunology Electroporation / methods Guinea Pigs Humans Immunization Mice Neoplasms / immunology, therapy Plasmids Treatment Outcome Vaccines, DNA* / administration & dosage, adverse effects, genetics, immunology |
| Grant Support | |
ID/Acronym/Agency:
|
HHSN272200800039C/AI/NIAID NIH HHS; HHSN272200800039C//PHS HHS; U01 AI061142/AI/NIAID NIH HHS; U01 AI061142-05/AI/NIAID NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/Adjuvants, Immunologic; 0/Cancer Vaccines; 0/Cytokines; 0/Vaccines, DNA |
| Comments/Corrections | |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Feasibility of cross-protective vaccination against flaviviruses of the Japanese encephalitis seroco...
Next Document: Remaining issues and challenges for rotavirus vaccine in preventing global childhood diarrheal morbi...